The stream · Daily digest
The stream: Tuesday, October 13, 2026
10 briefs from ClinicalTrials.gov, grouped by desk. Each is two sentences from one primary source, linked to it.
Machine-summarized from primary sources; not independently reported. How we use automation
Clinical trials · 7
-
AbbVie presents Phase 3 AFFIRM data showing endoscopic remission with SKYRIZI in Crohn's disease
The study reported that 35.8% of patients achieved endoscopic remission and 36.6% achieved ulcer-free endoscopy after subcutaneous SKYRIZI versus 10.2% and 10.2% with placebo. Safety findings through week 24 were consistent with the known safety profile of risankizumab, with no new safety signals.
Source: Company press release (PR Newswire), October 13, 2026
-
Huons Biopharma registers Phase 3 trial of HU-045 in glabellar lines
The study was first posted on ClinicalTrials.gov on October 13, 2026. It plans to enroll 390 participants and compares HU-045 to Xeomin in adults with moderate or severe glabellar lines.
Source: ClinicalTrials.gov registry record, October 13, 2026
-
Il-Yang Pharm. Co. registers Phase 3 trial of UROCOM-R1 plus UROCOM-R2
The study plans to enroll 660 participants and is expected to start on November 9, 2026. It plans to compare the efficacy and safety of UROCOM-R1 plus UROCOM-R2 combination therapy with UROCOM-R1 or UROCOM-R2 monotherapy in patients with benign prostatic hyperplasia.
Source: ClinicalTrials.gov registry record, October 13, 2026
-
Takeda registers Phase 3b trial of Zasocitinib in psoriatic arthritis
Takeda plans to enroll 644 participants in a Phase 3b study of Zasocitinib (TAK-279) for active psoriatic arthritis, with a start date of January 11, 2027. The trial is expected to reach primary completion on April 18, 2030.
Source: ClinicalTrials.gov registry record, October 13, 2026
-
GlaxoSmithKline registers Phase 3a study of recombinant zoster vaccine for cardiovascular events
The study, led by GlaxoSmithKline, plans to enroll 16,390 participants and aims to evaluate the impact of RZV on major adverse cardiovascular events in adults 50 years and older with established cardiovascular disease or two or more risk factors. It is scheduled to begin on November 30, 2026, with primary completion expected on November 25, 2032.
Source: ClinicalTrials.gov registry record, October 13, 2026
-
Lee's Pharmaceutical posts results of Phase 3 ciprofloxacin-fluocinolone otic solution trial
The study enrolled 600 participants and was completed in October 2021. It evaluated the efficacy and safety of ciprofloxacin 0.3% plus fluocinolone acetonide 0.025% otic solution versus ciprofloxacin 0.3% alone in acute otitis externa.
Source: ClinicalTrials.gov results record, October 13, 2026
-
Good Molecules posts results of Phase 3 facial toner study
The study enrolled 49 participants and evaluated a topical facial toner for improving skin lightness, texture and appearance in hyperpigmentation over 18 weeks. Results were first posted on ClinicalTrials.gov on October 13, 2026.
Source: ClinicalTrials.gov results record, October 13, 2026
Policy · 3
-
CMS announces $2.3 million RHTP funding for Missouri rural healthcare
The Trump Administration announced more than $2.3 million in Rural Health Transformation Program funding to Missouri, allocating $1.46 million for workforce recruitment and retention and $879,000 to launch a certified nurse midwife training program. The investment aims to expand childcare support for rural healthcare workers and increase maternal care access across the state.
Source: CMS press release, October 13, 2026
-
Paragon Labs expands leadership with former Apogee executives
Paragon Labs announced that former senior leaders from Apogee Therapeutics have joined its team, led by Michael Henderson, M.D., to support clinical development of Paragon-discovered assets. The move follows Apogee's 2026 acquisition by AbbVie for over $10.9 billion.
Source: Company press release (PR Newswire), October 13, 2026
-
Rona Therapeutics grants Roche exclusive worldwide license for ALK7-targeting RNAi therapy
Rona Therapeutics announced it has granted Roche an exclusive worldwide license for its investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7). The agreement gives Rona up to $100 million in upfront and near-term milestone payments and up to $1.06 billion in potential development, regulatory and commercial milestone payments, plus tiered royalties on global net sales.
Source: Company press release (PR Newswire), October 13, 2026